Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment after resection and platinum chemotherapy for stage II to IIIA non-small cell lung cancer with PD-L1 on at least 1% of tumor cells by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The decision uses postoperative stage and a tumor-cell PD-L1 threshold to select an adjuvant population.
What research teams should watch
Record pathologic stage, surgery and chemotherapy dates, and the assay-specific tumor-cell score.
PRIMARY RECORDS